[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-356340-105":59,"doc-detail-356340-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","prmt5-inhibitors-actively-promote-metastatic-progression-of-lung-adenocarcinoma","PRMT5 inhibitors actively promote metastatic progression of lung adenocarcinoma","","Epigenetic changes drive cancer progression and make epigenetic regulators key therapeutic targets. Protein arginine methyltransferase 5 (PRMT5) is one such regulator, with multiple PRMT5 inhibitors (PRMT5i) in clinical trials, yet PRMT5i-resistance mechanisms remain unclear. This study shows aggressive progression as an intrinsic feature of PRMT5i resistance in lung adenocarcinoma, via rapid chromatin rewiring and dedifferentiation that increases metastatic potential.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/prmt5-inhibitors-actively-promote-metastatic-progression-of-lung-adenocarcinoma/356340/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/prmt5-inhibitors-actively-promote-metastatic-progression-of-lung-adenocarcinoma/356340.png","ImageObject",300,407,{"name":92,"@type":93},"Hazel","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-30","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":39},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What is the study’s main finding about PRMT5 inhibitors in lung adenocarcinoma?","Question",{"text":112,"@type":113},"PRMT5 inhibitors actively promote metastatic progression, particularly as a built-in feature of acquired PRMT5i resistance in lung adenocarcinoma.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How do resistant cells change after PRMT5 inhibitor exposure?",{"text":117,"@type":113},"Independent resistant cell lines gain dedifferentiation signatures typical of late-stage disease and show increased metastatic potential in vivo.",{"name":119,"@type":110,"acceptedAnswer":120},"What mechanism does the study propose for PRMT5i-driven progression?",{"text":121,"@type":113},"PRMT5i treatment induces rapid and widespread chromatin rewiring that derepresses late-stage disease states, which then become stably established in resistant cells.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},356340,1790243982,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":39,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":24,"preview_urls":146},137441390410,"https://ap-avatar.wpscdn.com/avatar/2000252f4ab5702993?_k=1776741390130283984","bioRxiv preprint doi: [https://doi.org/10.64898/2026.01.30.702866](https://doi.org/10.64898/2026.01.30.702866); this version posted February 2, 2026. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made  \navailable under aCC-BY-NC-ND 4.0 International license.  \n1 PRMT5 inhibitors actively promote metastatic progression of lung adenocarcinoma 2  \n3 Colin E. Fowler 1,2, Natalie A. O’Hearn 1, Nicole Henning 1, Anthony Griffen3,4, Nicolas Mathey- 4 Andrews 1,2, Griffin J. Salus 1, Renin Hazan 1, Tyler Jacks 1,2, Aurora A. Burds 1, Helen S. Mueller5, 5 Yadira Soto-Feliciano 1,2, Lindsay M. LaFave3,4,6,7, Jacqueline A. Lees 1,2,*  \n6  \n7 1 The David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of  \n8 Technology, Cambridge, MA, USA  \n9 2 Department of Biology, Massachusetts Institute of Technology, Cambridge, MA, USA  \n10 3 Department of Cell Biology, Albert Einstein College of Medicine, Bronx, NY, USA  \n11 4 Montefiore Einstein Comprehensive Cancer Center, Albert Einstein College of Medicine, Bronx, 12 NY, USA  \n13 5 Molecular Pharmacology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer  \n14 Center, New York, NY, USA  \n15 6 Ruth L. and David S. Gottesman Institute for Stem Cell Biology and Regenerative Medicine, 16 Albert Einstein College of Medicine, Bronx, NY, USA  \n17 7 Cancer Dormancy & Tumor Microenvironment Institute, Albert Einstein College of Medicine, 18 Bronx, NY, USA  \n19 * Corresponding Author:  \n20 Jacqueline A. Lees  \n21 The David H. Koch Institute for Integrative Cancer Research & Department of Biology  \n22 Massachusetts Institute of Technology  \n23 500 Main Street, 76-261C, Cambridge, MA, 02139  \n24 E-mail: [jalees@mit.edu](jalees@mit.edu)  \n25 Phone: 617-252-1972  \nbioRxiv preprint doi: [https://doi.org/10.64898/2026.01.30.702866](https://doi.org/10.64898/2026.01.30.702866); this version posted February 2, 2026. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made  \navailable under aCC-BY-NC-ND 4.0 International license.  \n26 Abstract  \n27 Epigenetic changes are a major driver of cancer progression, placing considerable focus on  \n28 epigenetic regulators as therapeutic targets. Protein arginine methyltransferase 5 (PRMT5) is one  \n29 such regulator, and numerous PRMT5 inhibitors (PRMT5i) in clinical trials. Despite this, the  \n30 mechanisms and consequences of PRMT5i-resistance are unknown. Here, we demonstrate that  \n31 aggressive cancer progression is an inbuilt feature of PRMT5i-resistance acquisition in lung  \n32 adenocarcinoma (LUAD) . Independently-generated resistant cell lines gain dedifferentiation  \n33 signatures that typify late-stage disease and show increased metastatic potential in vivo. We  \n34 establish that these state shifts are a direct consequence of PRMT5i action; treatment induces rapid  \n35 and widespread chromatin rewiring, enabling derepression of late-stage disease states that are  \n36 stably established in resistant cells. Notably, treatment of lung tumor-bearing mice drives rapid  \n37 disease advancement without decreasing tumor burden, showing that drug-induced disease  \n38 progression supersedes any benefits from PRMT5 inhibition in vivo. Furthermore, analyses of  \n39 human cell lines and patient cohorts supports the notion of PRMT5 inhibition-mediated  \n40 dedifferentiation. Collectively our data show that PRMT5i can actively promote self-resistance  \n41 and disease progression in different tumor types. This raises serious concerns for the use of  \n42 PRMT5i in patients, arguing that clinical studies should consider the possibility of drug-induced  \n43 plasticity, resistance, and disease advancement.  \n44  \n45 Introduction  \n46 Though genetic mutations have critical tumor-i","cbCaigjQTgHBDQzh","https://ap.wps.com/l/cbCaigjQTgHBDQzh","pdf",16551335,46,"English","# Abstract\n# Introduction","[{\"question\":\"What is the study’s main finding about PRMT5 inhibitors in lung adenocarcinoma?\",\"answer\":\"PRMT5 inhibitors actively promote metastatic progression, particularly as a built-in feature of acquired PRMT5i resistance in lung adenocarcinoma.\"},{\"question\":\"How do resistant cells change after PRMT5 inhibitor exposure?\",\"answer\":\"Independent resistant cell lines gain dedifferentiation signatures typical of late-stage disease and show increased metastatic potential in vivo.\"},{\"question\":\"What mechanism does the study propose for PRMT5i-driven progression?\",\"answer\":\"PRMT5i treatment induces rapid and widespread chromatin rewiring that derepresses late-stage disease states, which then become stably established in resistant cells.\"}]","PRMT5 inhibitors actively promote metastatic progression of lung adenocarcinoma | PDF",1790124917,116,[147,151,155,159,163],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/db86976ef279d847c43154358a4dd91d.webp",983,1272,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/3ab8038fa0d8825d220ed8a3880343a9.webp",982,1270,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/7307b95b03a6c63416e0b3c2968f5b6c.webp",981,1269,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/4d547d3f8255338186d1459682585f5c.webp",980,1268,{"page_no":24,"url":164,"width":165,"height":166},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b9f9c88610d4f0759bcb2716e49902f0.webp",979,1267]